Publications:327
Jian Jin, PhD
About Me
Dr. Jian Jin is currently the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at Mount Sinai (Mount Sinai). He is also a tenured Full Professor in Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience as well as a Co-Leader of the Cancer Clinical Investigation Program at the Mount Sinai Tisch Cancer Center. Dr. Jin is an internationally recognized medicinal chemist and chemical biologist with >25 years of experience in small-molecule drug discovery. His laboratory is a leader in discovering novel degraders targeting oncoproteins, selective inhibitors of histone methyltransferases, and biased ligands of G protein-coupled receptors. Dr. Jin has published >300 peer-reviewed papers and delivered >160 invited talks. He is also an inventor of >90 issued U.S. patents and published patent applications. In particular, Dr. Jin is one of several inventors of Daprodustat, a hypoxia-inducible factor (HIF) prolyl hydroxylase small-molecule inhibitor, which has been approved in the United States and Japan as an oral medication for the treatment of anemia. Dr. Jin has been inducted to the National Academy of Inventors (NAI) as an NAI Fellow.
Dr. Jin received a Bachelor’s of Science degree in chemistry from University of Science and Technology of China in 1991 and a PhD in organic chemistry from the Pennsylvania State University in 1997. After completing a post-doctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC) as an Associate Professor. He had also served as an Associate Director of Medicinal Chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Dr. Jin was recruited to Mount Sinai as a Full Professor with tenure in 2014.
Complete list of published work in PubMed
Google scholar citations
Language
English
Position
PROFESSOR | Oncological Sciences, PROFESSOR | Pharmacological Sciences, PROFESSOR | Neuroscience
Research Topics
Cancer, Chromatin, Drug Design and Discovery, Epigenetics, Membrane Proteins/Channels, Neuroscience, Protein Degradation, Structural Biology
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Education
BS, University of Science and Technology of China
PhD, Pennsylvania State University
Postdoc, Ohio State University
Research
The Jin lab is a leader in developing novel degraders targeting oncogenic proteins. Since 2014, the lab has discovered and characterized a number of first-in-class degraders using the PROTAC (proteolysis targeting chimera) and hydrophobic tagging technologies. Our degrader program has resulted in multiple patent applications filed by Mount Sinai.
Publications
Selected Publications
- SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma. Zhihui Liu, Sukriti Bagchi, Chunhua Yan, Ying Hu, Gil Blum, Anqi Ma, Jian Jin, Minkui Luo, Sebastiano Di Bella, Francesco Verona, Ettore Appella, Giuseppe Giannini, Carol J. Thiele, Veronica Veschi. Journal of Experimental and Clinical Cancer Research
- Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation. Pengcheng Gao, Yue Zhong, Kaixiu Luo, Jian Jin. Advanced Drug Delivery Reviews
- Discovery of KRAS-G12D degraders via exploration of various E3 ligases. Hyerin Yim, Xiangyang Song, Yue Zhong, Jacqueline Hu, Yan Xiong, Jian Jin. European Journal of Medicinal Chemistry
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Jin during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Petra Pharma Corporation
- Onsero Therapeutics
- Accent Therapeutics, Inc.
- Cullgen, Inc.
- EpiCypher, Inc.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Cullgen, Inc.
Founder/Co-Founder/Partner
- Cullgen, Inc.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.